Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates
- 1 May 2002
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 61 (5) , 974-981
- https://doi.org/10.1124/mol.61.5.974
Abstract
Using in vitro data, we previously built Catalyst 3-dimensional quantitative structure activity relationship (3D-QSAR) models that qualitatively rank and predict IC50 values for P-glycoprotein (P-gp) inhibitors. These models were derived and tested with data for inhibition of digoxin transport, calcein accumulation, vinblastine accumulation, and vinblastine binding. In the present study, 16 inhibitors of verapamil binding to P-gp were predicted using these models. These inhibition results were then used to generate a new pharmacophore that consisted of one hydrogen bond acceptor, one ring aromatic feature, and two hydrophobes. This model predicted the rank order of the four data sets described previously and correctly ranked the inhibitory potency of a further four verapamil metabolites identified in the literature. The degree of similarity in rank ordering prediction by these inhibitor pharmacophore models generated to date confirms a likely overlap in the sites to which the three P-gp substrates used in these studies (verapamil, vinblastine, and digoxin) bind. Alignment of the three substrate probes indicated that they are likely to bind the same or overlapping sites within P-gp. Important features on these substrates include multiple hydrophobic and hydrogen bond acceptor features, which are widely dispersed and in agreement among most of the five inhibitor pharmacophores we have described so far. These 3D-QSAR models will be useful for future prediction of likely substrates and inhibitors of P-gp.Keywords
This publication has 17 references indexed in Scilit:
- Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-GlycoproteinMolecular Pharmacology, 2002
- Competitive and Allosteric Interactions in Ligand Binding to P-glycoprotein as Observed on an Immobilized P-glycoprotein Liquid Chromatographic Stationary PhaseMolecular Pharmacology, 2001
- Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolitesInt. Journal of Clinical Pharmacology and Therapeutics, 2000
- Stimulation of P‐glycoprotein‐mediated drug transport by prazosin and progesteroneEuropean Journal of Biochemistry, 1999
- Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-GlycoproteinPharmaceutical Research, 1999
- Evaluation of Atypical Cytochrome P450 Kinetics with Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active SitesBiochemistry, 1998
- Evidence for two nonidentical drug-interaction sites in the human P-glycoproteinProceedings of the National Academy of Sciences, 1997
- P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct GroupsMolecular Pharmacology, 1997
- Co-operative, competitive and non-competitive interactions between modulators of P-glycoproteinBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1996
- Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.Proceedings of the National Academy of Sciences, 1989